Print Departments and specialties Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery. Departments with related expertise Breast Clinic Cancer Care at Mayo Clinic Cancer survivorship clinics Oncology (Medical) Women's Health Doctors who perform this procedure Edit search filters close Narrow your search By location Jacksonville, FL By last name There are no doctors whose last name begins with the letter A A There are no doctors whose last name begins with the letter B B There are no doctors whose last name begins with the letter C C There are no doctors whose last name begins with the letter D D There are no doctors whose last name begins with the letter E E There are no doctors whose last name begins with the letter F F There are no doctors whose last name begins with the letter G G There are no doctors whose last name begins with the letter H H There are no doctors whose last name begins with the letter I I There are no doctors whose last name begins with the letter J J There are no doctors whose last name begins with the letter K K There are no doctors whose last name begins with the letter L L Find a doctor whose last name begins with the letter M M There are no doctors whose last name begins with the letter N N There are no doctors whose last name begins with the letter O O There are no doctors whose last name begins with the letter P P There are no doctors whose last name begins with the letter Q Q There are no doctors whose last name begins with the letter R R There are no doctors whose last name begins with the letter S S There are no doctors whose last name begins with the letter T T There are no doctors whose last name begins with the letter U U There are no doctors whose last name begins with the letter V V There are no doctors whose last name begins with the letter W W There are no doctors whose last name begins with the letter X X There are no doctors whose last name begins with the letter Y Y There are no doctors whose last name begins with the letter Z Z Reset all filters Search Tips Use quotes for phrases. Even if there are no auto-suggestions within the search field, hit "Search" anyway, as you may still get results. Displaying 1-1 out of 1 doctors available Sarah A. McLaughlin, M.D. Surgical Oncologist Jacksonville, FL Areas of focus: Mastectomy, Lumpectomy, Breast surgery, Breast reconstruction, Breast cancer surgery, Oncoplastic breast-conserving sur...gery, Modified radical mastectomy, Double mastectomy, Estrogen blocker therapy for breast cancer, Breast cancer, Lymphedema, Triple-positive breast cancer, High risk for breast cancer Show more areas of focus for Sarah A. McLaughlin, M.D. Research Profiles Edit search filters close Narrow your search By location Arizona Florida Minnesota View all View all physicians • All Locations Ames, Matthew M. Ph.D. Minnesota Cronin, Patricia A. M.D. Arizona Goetz, Matthew P. M.D. Minnesota Muthusamy, Kalpana M.D. Minnesota Pockaj, Barbara A. M.D. Arizona Pruthi, Sandhya M.D. Minnesota Vachon, Celine M. Ph.D. Minnesota By Mayo Clinic Staff Request an appointment About Aug. 28, 2026 PrintShow references Breast cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed Aug. 3, 2026. Hormone therapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/hormone-therapy. Accessed Aug. 3, 2026. Allison KH, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. Journal of Clinical Oncology. 2020; doi:10.1200/JCO.19.02309. Burstein HJ, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. Journal of Clinical Oncology. 2019; doi:10.1200/JCO.18.01160. Burstein HJ, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. Journal of Clinical Oncology. 2021; doi:10.1200/JCO.21.01392. Papakonstantinou A, et al. Adjuvant endocrine treatment strategies for non-metastatic breast cancer: A network meta-analysis. eClinicalMedicine. 2025; doi:10.1016/j.eclinm.2025.103116. Pala L, et al. Tailoring the optimal duration of extended adjuvant endocrine therapy in patients with early-stage breast cancer: A systematic review and meta-analysis of randomized clinical trials. The Breast. 2023; doi:10.1016/j.breast.2023.02.012. Klimberg VS, et al., eds. Systemic therapy of hormone-sensitive HER2-negative breast cancer: Adjuvant and neoadjuvant. In: Bland and Copeland's The Breast: Comprehensive Management of Benign and Malignant Diseases. 6th ed. Elsevier; 2024. https://www.clinicalkey.com. Accessed Aug. 3, 2026. Zuo H, et al. Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation. European Journal of Cancer. 2025; doi:10.1016/j.ejca.2025.115665. Eliassen FM, et al. Importance of endocrine treatment adherence and persistence in breast cancer survivorship: A systematic review. BMC Cancer. 2023; doi:10.1186/s12885-023-11122-8. AskMayoExpert. Invasive breast cancer: Survivorship. Mayo Clinic; 2021. Gradishar WJ, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2024. Journal of the National Comprehensive Cancer Network. 2024; doi:10.6004/jnccn.2024.0035. Gradishar WJ, et al. NCCN Guidelines Insights: Breast Cancer, Version 5.2025. Journal of the National Comprehensive Cancer Network. 2025; doi:10.6004/jnccn.2025.0053. Ma Y, et al. Symptom experience in endocrine therapy for breast cancer patients: A qualitative systematic review and meta-synthesis. Asia-Pacific Journal of Oncology Nursing. 2024; doi:10.1016/j.apjon.2023.100364. Orserdu (prescribing information). Stemline Therapeutics Inc.; 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef. Accessed Aug. 10, 2026. Medical review (expert opinion). Mayo Clinic. Aug. 7, 2026. Campone M, et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. New England Journal of Medicine. 2025; doi:10.1056/NEJMoa2505725. Related Breast cancer ER positive breast cancer Triple-positive breast cancer News from Mayo Clinic The 4 types of systemic therapy for breast cancer Mayo Clinic treats first person in the US with a novel radiopharmaceutical therapy for breast cancer Mayo Clinic collaborates on new drug study showing improved survival for early breast cancer Estrogen blocker therapy for breast cancerAboutDoctors&Departments PRC-20213600 Tests & Procedures Estrogen blocker therapy for breast cancer